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Leprosy exhibits a wide range of cell-mediated responses resulting in disease 
states ranging from benign tuberculoid to multibacillary, lepromatous states (1). 
The skin lesions of tuberculoids show organized granuloma, many Leu 3a/OKT4 
helper T  cells, and good T  cell proliferative responses to the specific organisms. 
In contrast, lepromatous disease is characterized by a deficient cellular response 
with the predominance of Leu 2a/OKT8 suppressor/cytotoxic cells in the dermis, 
the presence of bacilli-laden macrophages, and the absence of T cell proliferative 
responses (2-3). 
Recent evidence has implicated 3' interferon (3,-IFN) as the important macro- 
phage-activating factor  in  lymphokine preparations  in  both  tumoricidal  and 
microbicidal systems (4-7).  These results led us to examine the production of 
this lymphokine in patients with a  spectrum of lepromatous, intermediate, and 
tuberculoid disease. During the course of these studies, a report by Haregewoin 
et al. (8) suggested that lepromatous lymphocytes failed to make interleukin 2 
. (IL-2) and that a crude supernatant containing IL-2 restored their proliferative 
responses to specific antigen. 
We now report that the peripheral blood lymphocytes of patients with lepro- 
matous  leprosy  failed  to  produce  ~-IFN  upon  exposure  to antigen and  had 
reduced responses to mitogen. This deficiency was restored by the addition of a 
purified human IL-2. 
Material and Methods 
Patients.  After informed consent, skin and heparinized peripheral blood was collected 
from 20 patients in Brazil and 14 patients in the U. S. Brazilian patients were studied in 
collaboration with the Departments of Dermatology and General Pathology, Hospital das 
Clinicas, Universidade do Estado do Rio de Janeiro. In the U. S., patients were obtained 
through the Staten  Island  Public Health Hospital in New York. Clinical diagnosis was 
established  by Dr. Jarbas  A.  Porto in  Brazil and  Dr.  W.  Levis in  the  United States. 
Histologic diagnosis was established according to the Ridley-Jopling classification (9) by 
Dr. E. Sarno in Brazil and, in the U. S., Dr. C. K. Job of the National Hansen's Disease 
Center, Carville, LA. 
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Production of "y-IFN by Peripheral Blood Mononuclear Cells.  Peripheral blood mononuclear 
cells (PBMC),  obtained as previously described (10), were suspended to 3 ×  106/ml in 
RPMI containing 20% autologous human plasma, penicillin (1,000 U/ml), streptomycin 
(100  #g/ml),  and  L-glutamine (2  mM).  Cells  were  incubated  in  24-well  Costar  plates 
(Costar, Data Packaging, Cambridge, MA) in the~resence ofMycobacterium leprae (2.5 #g/ 
ml) or concanavalin A (Con A) (15 #g/ml). Controls included cells cultured in medium 
alone, as well as cells first cultured in medium alone for the appropriate time, with Con 
A and M. leprae added at the end of the incubation period. M. leprae was kindly provided 
by Dr. R.J.W.  Rees (IMMLEP Bank), The National Institute of Medical Research, The 
Ridgeway, Mill Hill, England and Dr. P. Brennan of the Department of Microbiology, 
Colorado State  University,  Ft.  Collins,  Colorado.  Culture media  were harvested as  a 
source of immune IFN at 2 d (Con A) or 5 d (M. leprae) unless otherwise stated, and kept 
frozen (-20°C) until used. 
~,-IFN Assay.  Antiviral activity was determined by the reduction in encephalomyocar- 
ditis virus cytophatic effect on human foreskin cells (FS4) grown on microtiter plates (11). 
Antiviral activity expressed in IFN units was calculated as the reciprocal of the highest 
dilution of the  sample that  reduced the  viral cytophatic effect by  50%.  A  laboratory 
standard for human 7-IFN was included in each assay. All titers were expressed in actual 
laboratory units without correction. Antiviral activity was  determined to be 7-IFN  by 
neutralization assays using a rabbit anti-7-serum (12). 
IL-2 Purification.  PBMC purified as described above (3 ×  106/ml) were stimulated for 
30 h in the presence of 10 #g/ml Con A and 10 ng/ml phorbol myristate acetate (PMA) 
in RPMI medium containing 2% human serum albumin. One liter of conditioned medium 
was concentrated 10x using a YM  10 Amicon membrane (Amicon Corp., Danvers, MA), 
dialyzed against 20 mM Na citrate, pH 5.5, and loaded on 20-ml column of SP-Sephadex 
C-25 (Pharmacia Fine Chemicals, Piscataway, NJ) equilibrated in 20 mM Na citrate, pH 
5.5. The column was washed with the equilibration buffer and IL-2 activity was eluted 
with increasing salt concentration. Fractions containing IL-2 activity (between 0.15 and 
0.30 M NaCl) were pooled and dialyzed against 50 mM Tris HCI, pH 7.8, and loaded on 
a 20-ml column of DEAE-52 cellulose (Whatman Laboratory Products, Inc., Clifton, NJ) 
equilibrated with 50 mM Tris HCI, pH  7.8, IL-2 was eluted using a linear gradient of 
NaCI  (0-0.2 M) in 50 mM Tris HCI, pH 7.8. The active fractions (0.05-0.07 M NaC1) 
were  pooled,  dialyzed  against  phosphate-buffered saline  (PBS),  and  loaded  in  10-ml 
column of blue agarose (Bio-Rad Laboratories, Richmond, CA) equilibrated in PBS. IL-2 
activity was  eluted using a  linear gradient of NaCI (0.15-1  M) in  PBS.  The resulting 
fractions with IL-2 activity (0.6-0.75 M NaCI)  were pooled, concentrated, and dialyzed • 
against 0.05% sodium dodecyl sulfate (SDS). Aliquots were electrophoresed in a  12.5% 
SDS-polyacrylamide gel electrophoresis (PAGE). The gel was cut into 1-mm slices, eluted 
in PBS for 18 h at 4  C, and assayed for IL-2 activity. The active fractions were pooled 
and kept at 4°C. This IL-2 preparation contained 250 U/ml and displayed a single band 
when run in SDS-PAGE and stained with the silver method, and was completely devoid 
of IFN  activity. One  unit corresponded to the  minimum amount of IL-2 required to 
double the [3H]thymidine incorporation observed in untreated control cultures using for 
the IL-2 bioassay 2 ×  104 Con A-stimulated spleen cells (13). 
['~H]Thymidine Incorporation.  After the appropriate incubation, cells  were harvested 
and  resuspended  to  2  x  106  cells/ml  in  20%  autologous plasma  as  described above. 
Triplicate samples containing 2 x  105 cells/well were plated in 96-well  round-bottomed 
trays (Linbro) and 1 uCi [3H]thymidine added per well. The cells were incubated for 18 
h at 37°C, harvested, and counted in a scintillation counter. 
Immunofluorescence Assays.  Assays were carried out as previously described (4). 
Results 
7-IFN Release  by PBMC from  Leprosy Patients.  PBMC  from  34  patients  were 
analyzed for their ability to generate y-IFN in response to the specific antigen 
M. teprae or to the mitogen Con A,  17 of 18 lepromatous leprosy and borderline NOGUEIRA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
7-IFN Release by PBMC from Leprosy Patients 
2167 
Treatment  Clinical  Histological 
Patient  duration  diagnosis*  diagnosis 
3'-IFN titer 
+ M. leprae  + Con A 
1 (SRG)  None  L  LL  <4  <4 
2 (EAS)  None  L  LL  <4  <4 
3 (AA)  1 yr  L  LL  <4  <4 
4 (CL)  2 yr  L  BL  <4  <4 
5 (APA)  None  L  LL  <4  <4 
6 (FL)  <1 yr  L  LL  <4  <4 
7 (DMCO)  None  L  I  <4  <4 
8 (CCB)  None  L  LL  <4  <4 
9 (FBB)  None  L  LL  <4  32 
10 (AR)  >5 yr  L  LL  <4  8 
11 (SK)  >1 yr  L  LL  8  32 
12 (AW)  >5 yr  L  LL  <4  8 
13 (CBS)  None  L  BL  <4  <4 
14 (RM)  3 yr  L  BL/LL  16  8 
15 (FEG)  <1 yr  L  BL  8  15 
16 (AW)  >1 yr  B  LL  <4  64 
17 (R)  None  L  LL  4  32 
18 (JB)  None  B  BL  <4  256 
19 (CTR)  None  B  BB  4  16 
20 (MDV)  None  L  BB  <4  32 
21 (MA)  None  T  TT  <4  256 
22 (S)  >1 yr  T  NSI;  64  16 
23 (ML)  10 yr  T  ND  !  32  64 
24 (GB)  >5 yr  L  BB  32  2,048 
25 (JTL)  None  T  TT  16  512 
26 (MGSC)  None  B  BT  16  256 
27 (RJF)  None  T  BT  16  256 
28 (VS)  >5 yr  T  ND  64  64 
29 (RCMP)  None  B  BT  128  512 
30 (RS)  5 yr  T  BT  128  128 
31 (MV)  1 yr  T  BT  256  ND 
32 (BFBS)  None  T  TT  256  256 
33 (CR)  None  T  TT  128  4,096 
34 (IP)  >1 yr  T I  ND  I  128  ND 
* L, lepromatous; B, borderline; T, tuberculoid. 
* Nonspecific infiltrate; active erythema nodusum leprosum (ENL) reaction. 
! Not done, 
I BT neural. 
lepromatous patients (LL and BL) failed to generate 3'-IFN in response to antigen 
and  were similarly unresponsive  to  Con  A  (Table  I),  despite  their  showing 
proliferative responses to mitogen (not shown). Patients with the mid-borderline 
form of leprosy (BB) and a few patients with a histological diagnosis of borderline 
tuberculoid and tuberculoid leprosy (BT-TT) displayed intermediate responses. 
Six typical tuberculoid patients (BT-TT) showed vigorous 3,-IFN production in 
response to both antigen and mitogen. Low ~,-IFN production in response to 
antigen was observed not only in untreated lepromatous patients, but also in 
lepromatous patients who had been under chemotherapy for different lengths 
of time (Table I). 
Omission of the antigen or mitogen during the incubation period (medium 
alone) or the addition of antigen or mitogen at the end of the incubation period 
(Con A control and M. leprae control) were without effect on "y-IFN production. 
In all cases,  the antiviral activity could be specifically neutralized by a  rabbit 2168  NOGUEIRA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Effect of lL-2 on 7-IFN Release 
Patient 
7-1FN Titer 
Clinical  Without M. leprae  With M. leprae 
Treat-  diagno-  Histological 
ment  diagnosis  sis*  +  1L-2  +  IL-2 
-  IL-2  IL-2 
1 U/ml  5 U/ml  i  U/ml  5  U/ml 
Lepromatous 
FEG 1  <1 yr  L  LL  <4  16  ND*  8  128  ND 
RM 2  3 yr  L  BL/LL  <4  8  ND  16  128  ND 
CL 3  2 yr  L  BL  <4  32  32  16  128  512 
GB 4  >5 yr  L  BL/BB  <4  <4  32  32  64  !,024 
AL 5  1 yr  L  LL  <4  <4  8  <4  4  16 
EG 6  1 yr  L  LL  <4  <4  32  <4  32  64 
SK 7  >1 yr  L  LL  <4  <4  <4  <4  64  64 
AR 8  >5 yr  L  LL  <4  <4  <4  <4  4  4 
AW 9  >5 yr  L  LL  <4  <4  <4  <4  4  8 
Tuberculoid 
IP  >1 yr  T !  ND  <4  8  16  128  128  256 
US  >5 yr  T  ND  <4  <4  <4  64  64  64 
Control 
individuals 
AW  <4  <4  4  <4  <4  <4 
JH  <4  4  8  4  <4  16 
JA  <4  ND  ND  <4  ND  ND 
A  <4  <4  4  16  16  64 
PK (male)  <4  <4  4  <4  16  64 
PK (female)  <4  8  4  <4  4  32 
* L, lepromatous; T, tuberculoid. 
* Not done. 
!  BT neural. 
antiserum against -y-IFN (not shown). This includes the antiviral activity observed 
in PBMC  from iepromatous patients stimulated by antigen or mitogen in the 
presence of a purified IL-2. 
Restoration of "y-IFN Production in Lepromatous and Tuberculoid Patients.  In view 
of the absent IL-2 response by lepromatous cells (9), we examined the effects of 
a purified IL-2 preparation on 7-IFN formation. The addition of 1-5 U/ml of 
IL-2, in the presence of M. leprae antigen, led to a significant increase in 7-IFN 
production in lepromatous patients (Table II). The levels achieved were similar 
to those produced by antigen-triggered  PBMC from tuberculoid patients and 
seemed related  to  their  initial responsiveness to M.  leprae. IL-2  also  restored 
responsiveness to Con A  and was accompanied by a  10-fold increase in [SH]- 
thymidine incorporation (not shown). Neither unsensitized control subjects nor 
patients with tuberculoid leprosy demonstrated enhanced "y-IFN  release in the 
presence of IL-2 and M.  leprae antigen. Control subjects were unresponsive to 
the antigen and tuberculoid patients were already making good amounts of 7- 
IFN in response to antigen and mitogen in the absence of added IL-2. 
Correlation  of Helper  Suppressor  Ratio  in  Skin  Biopsies and  PBMC  7-IFN  Re- 
lease.  Levels of 7-IFN released correlated more closely with the ratio of helper/ 
suppressor (OKT4/OKT8)  cells in cutaneous lesions than with histological di- 
agnosis, particularly in borderline cases (Tables I and II); ie., 7-IFN unrespon- 
siveness was associated with a low helper/suppressor ratio (not shown). In some 
cases, patients classified as TT or BT by histological means (not shown) displayed 
low "y-IFN levels and a low OKT4/OKT8  ratio. NOGUEIRA  ET  AL.  BRIEF  DEFINITIVE  REPORT  2169 
Discussion 
We describe in this report a  selective defect in the production of 3"-IFN by 
PBMC  of patients  with  iepromatous leprosy,  whereas  cells  from  those  with 
tuberculoid disease release readily detectable 3"-IFN. Hyporesponsiveness was 
most strikingly demonstrated in response to specific M. leprae antigen, but was 
also observed when cells from lepromatous patients were challenged with the 
polyclonal activator Con A. This is in keeping with the recently reported deficit 
in IL-2 production (9) and the well-known absence of a proliferative response 
(2, 3). Indeed, the addition of purified human IL-2 as well as antigen resulted in 
a  marked  restoration  of 3"-IFN production.  This  fact,  in  turn,  leads  to  the 
conclusion that  IL-2 is a  necessary but not sufficient element in the chain of 
events that ultimately results in the production of 3"-IFN. 
The preponderance of Leu 2a/OKT8  (suppressor/cytotoxic) T  cells in skin 
lesions was associated with the lack of IL-2 production by PBMC. This raises the 
possibility that suppressor T  cells, or their products, may influence IL-2 produc- 
tion as they do in other systems (14,  15). The absence of this mediator might 
then lead either to defective expansion of specifically sensitized T  cells able to 
release 3"-IFN or the failure to trigger them for 3"-IFN release. Consequently, no 
activation of macrophages occurs at the site. These hypotheses are being cur- 
rently investigated. Recent studies (16) have indicated that IL-2 induces B cell 
helper factor production in stimulated mouse T  cells. 
These results suggest that the absence of 3,-IFN production is correlated with 
the  defect in  cell-mediated immunity. In  the  lepromatous state,  the  lack  of 
macrophage activation may provide a fertile intracellular milieu for the uncon- 
trolled replication of the bacilli. In addition, the small local T  cell infiltrate and 
the absence of helper T  cells complicate dermal responsiveness. 
The unresponsiveness of peripheral blood T  cells is more closely correlated 
with the helper/suppressor T  cell ratios of the skin than with the histological 
scoring index. This may reflect both the heterogeneity of the local skin lesions 
and the general lack of parenteral responsiveness. In this sense, the quantitative 
assay of 3,-IFN  production may prove to be a  useful prognosticator of cellular 
immunity and may reflect on the patient's subsequent course. 
The presumed in vivo importance of macrophage activation for the control of 
bacillary replication and the restorative qualities of IL-2 or 3"-IFN production 
suggests future clinical applications of these molecules. Both 3"-IFN and IL-2 will 
soon become available in relatively large quantities through recombinant DNA 
technology. Their local and/or parenteral administration as replacement immu- 
notherapy in lepromatous disease may serve as an adjunct to chemotherapy. 
Summary 
Antigen and mitogen-induced 3' interferon (3"-IFN) production was studied in 
peripheral blood mononuclear cells from 34 leprosy patients. 17 of 18 leproma- 
tous leprosy and borderline lepromatous patients (LL and BL) failed to release 
3,-IFN in response to specific antigen (Mycobacterium leprae) and displayed reduced 
responses to mitogen (concanavalin A) stimulation. In contrast, cells from six 
tuberculoid and borderline tuberculoid patients (TT and BT) produced consid- 
erable levels of 3"-IFN under the same experimental conditions. Normal controls 2170  NOGUEIRA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
failed to respond to M. leprae and most displayed good responses to concanavalin 
A. Mid-borderline patients (BB) showed intermediate levels of ~-IFN release. ~- 
IFN  release by lepromatous  patients  could  be partially  restored with  purified 
interleukin 2 and M. leprae antigen but not with interleukin 2 alone. 
Received for publication 26 September 1983. 
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